New Insights into Diagnostic and Prognostic Biomarkers of Amyotrophic Lateral Sclerosis: Must Innovative Findings Come from New Targets?
A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Biomarkers".
Deadline for manuscript submissions: 15 June 2024 | Viewed by 225
Special Issue Editor
Special Issue Information
Dear Colleagues,
Amyotrophic lateral sclerosis (ALS) remains a hot topic in the field of neurological research as no diagnosis, prognosis, and efficient treatment are available today. Although progress in exploratory methods is revolutionizing the research, especially on biomarkers, and the diversity of experimental models offers new opportunities to depict ALS, the topic of whether knowledge improvement must mandatorily come from rupture innovation is still up for debate. More specifically, we can suspect that the deep exploration of some targets has been abandoned to move toward more attractive and spectacular ones. Similarly, basic exploration methods for biomarkers have been replaced by omics, and standard data analysis has been replaced by artificial intelligence. However, research on more powerful and ambitious approaches may hide relevant findings based on more standard methods.
This Special Issue of Biomolecules will focus on the most recent advances in relation to 1) well-known targets described for many years but explored in different ways (SOD1, TDP-43, etc.), 2) isolated biomarkers provided by both targeted methods and large omics strategies, 3) promising results from standard experimental models, even if old and questionable, and 4) the mode effect via the exploration of ways largely described in several neurological diseases but rarely in ALS.
Both research (in particular) and review articles proposing novelties or overviews, respectively, are welcome.
Dr. Hélène Blasco
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biomarkers
- omics
- animal models
- innovation
